The company's strategic brands accounted for 77% of total revenue, totaling DKK 10.46 billion. Vyepti stood out with a 46% surge in underlying growth, while Rexulti contributed a 16% increase. These results reflect a broader transition to a partnership model across 27 markets, a shift the company maintains is proceeding according to its long-term plan.
Lundbeck Revenue Climbs 16% as Migraine Drug Vyepti Leads Growth
Driven by the commercial success of its migraine treatment Vyepti and the antipsychotic Rexulti, Denmark-based Lundbeck reported a 16% increase in revenue at constant exchange rates for the first half of 2026. The company reached DKK 13.59 billion in total revenue, bolstered by double-digit gains in the U.S. and Europe.
Profitability also showed improvement, with adjusted EBITDA rising 19% to DKK 4.77 billion. CEO Charl van Zyl noted that the company is advancing its pipeline, having recently completed enrollment for the phase III DEEp OCEAN trial of bexicaserin. Looking ahead, Lundbeck is positioning itself for the next phase of its strategy following the FDA’s recent Fast Track designation for its investigational sleep disorder compound, Lu AH69593.
Comments (0)
No comments yet. Be the first!